In regard to the immune system, anti-inflammatory properties of LRRK2 inhibitors may contribute to a disease modifying mechanism for PD, potentially via down regulation of microglia or modulating peripheral immunity. The gene discussed is LRRK2; the disease is Parkinson disease.